a positive trendgold
The RHODOS trial failed to show a benefit for its pre-specified primary end point (best recovery of visual acuity at week 24), but all of the secondary end points showed a positive trend towards visual improvement in the idebenone-treated group ( Klopstock et al., 2011 ).